LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOWTO CHOOSETHE PATIENT?

Атеротромбоз

A. L. Komarov¹ 

[1] A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Research and Production Complex;

关键词: acute coronary syndrome;    anticoagulant treatment;    warfarin;    rivaroxaban;   

DOI  :  10.21518/2307-1109-2016-1-26-38

来源: DOAJ

【 摘 要 】

The review tells about challenges  of antithrombotic  therapy in patients after acute coronary syndrome. The efficacy and safety of long-term administration of anticoagulants (warfarin as well as novel anticoagulants), in addition to standard antiplatelet therapy, is discussed. The focus is on rivaroxaban, low doses of which are officially indicated  for the prevention of cardiovascular  death and myocardial infarction in patients after acute coronary syndrome occurring with increased values of myocardial injury markers. Clinical characteristics of patients feasible for this treatment approach are considered.

【 授权许可】

Unknown